The estimated Net Worth of Richard K Prins is at least $4.57 Million dollars as of 12 August 2024. Mr. Prins owns over 17,101 units of Amphastar Pharmaceuticals Inc stock worth over $2,301,815 and over the last 15 years he sold AMPH stock worth over $1,959,601. In addition, he makes $313,007 as Lead Independent Director at Amphastar Pharmaceuticals Inc.
Richard has made over 46 trades of the Amphastar Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 17,101 units of AMPH stock worth $339,113 on 12 August 2024.
The largest trade he's ever made was exercising 329,583 units of Amphastar Pharmaceuticals Inc stock on 13 March 2024 worth over $14,854,306. On average, Richard trades about 20,251 units every 62 days since 2009. As of 12 August 2024 he still owns at least 51,072 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Mr. Prins stock trades at the bottom of the page.
Richard K. Prins serves as Lead Independent Director of the Company. Since 2008, Mr. Prins has served as a member of our board of directors since February 2002. Since 2008, Mr. Prins has been a private investor and involved in various charitable organizations. Mr. Prins also volunteers as acting head of U.S. Operations for Advancing Native Missions and serves on the board of directors of India Globalization Capital, Inc. Mr. Prins was the Director of Investment Banking for FBW, from 1996 until June 2008 when FBW was acquired by Royal Bank of Canada and served as a consultant to Royal Bank of Canada Capital Markets through December 2008. Prior to FBW, Mr. Prins was a Managing Director from July 1988 to April 1996 at Crestar Bank (now SunTrust Bank) in charge of mergers and acquisitions. Mr. Prins began his career in 1983 as the Assistant to the Chairman of the leverage buyout company, Tuscarora Corp., where he held various positions until July 1988. Mr. Prins received a B.A. in liberal arts from Colgate University and an M.B.A. from Oral Roberts University.
As the Lead Independent Director of Amphastar Pharmaceuticals Inc, the total compensation of Richard Prins at Amphastar Pharmaceuticals Inc is $313,007. There are 10 executives at Amphastar Pharmaceuticals Inc getting paid more, with Jack Zhang having the highest compensation of $5,969,740.
Richard Prins is 62, he's been the Lead Independent Director of Amphastar Pharmaceuticals Inc since 2019. There are 8 older and 7 younger executives at Amphastar Pharmaceuticals Inc. The oldest executive at Amphastar Pharmaceuticals Inc is Richard Koo, 79, who is the Independent Director.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins, and William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: